


HYPERLIPIDEMIA



Algorithm for managing dyslipidemias in kidney transplant recipients

Units are in mg/dL. HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides; TLC = therapeutic lifestyle changes.⁽¹⁾

- The KDOQI and NCEP guidelines set an LDL treatment threshold of 100 mg/dL, and possibly even 70 mg/dL in very high-risk patients.⁽¹⁾⁽²⁾
- **Fluvastatin** and **pravastatin** have minimum interactions with immunosuppressive therapy.⁽²⁾⁽³⁾⁽⁴⁾
- **Ezetimibe** can be used in cases of statin resistance.⁽⁵⁾

- (1) Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3): I-IV, S1-S91.
- (2) Kasiske BL, de Mattos A, Flechner SM et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392.
- (3) Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., ... Pedersen, T. R. (2003). Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. The Lancet, 361(9374), 2024-2031.
- (4) Tokumoto, T., Tanabe, K., Ishida, H., Shimmura, H., Ishikawa, N., Goya, N., ... Toma, H. (2004). Impact of fluvastatin on hyperlipidemia after renal transplantation. Transplantation Proceedings, 36(7), 2141-2144.
- (5) Oppenheimer F, Alonso A, Arias M, Campistol JM, González Molina M, González Posada JM, Grinyo JM, Morales JM, Sánchez Fructuoso A, Sánchez-Plumed J, Ruiz JC. Handling sirolimus in clinical practice. Spanish Nephrology Society. Nefrologia. 2006;26 Suppl 2:64-93. English, Spanish. PMID: 17937635.

